CYP2E1*5B, CYP2E1*6, CYP2E1*7B, CYP2E1*2, and CYP2E1*3 Allele Frequencies in Iranian Populations

被引:19
作者
Shahriary, Ghazaleh Mohammadzadeh [1 ]
Galehdari, Hamid [1 ]
Jalali, Amir [3 ,4 ]
Zanganeh, Fatemeh [5 ]
Alavi, Seyed Mohammad Reza [2 ]
Aghanoori, Mohammad Reza [6 ]
机构
[1] Shaheed Chamran Univ, Fac Math, Dept Genet, Ahvaz, Iran
[2] Shaheed Chamran Univ, Fac Math, Dept Stat, Ahvaz, Iran
[3] Jundishapur Univ Med Sci Ctr, Sch Pharm, Dept Pharmacol & Toxicol, Ahvaz, Iran
[4] Jundishapur Univ Med Sci Ctr, Toxicol Res Ctr, Dept Pharmacol & Toxicol, Ahvaz, Iran
[5] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmacol & Toxicol, Tehran, Iran
[6] Shiraz Univ Med Sci, Dept Med Genet, Shiraz, Iran
关键词
Cytochrome P450; polymorphism; genotyping; allele frequency; Iranian population; CYTOCHROME-P450; 2E1; CANCER SUSCEPTIBILITY; GENETIC POLYMORPHISMS; CYP2E1; POLYMORPHISMS; RISK; ALCOHOL; CYP1A1; GSTM1; NAT2; ASSOCIATION;
D O I
10.7314/APJCP.2012.13.12.6505
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: CYP2E1 encodes an enzyme which is mainly involved in bioactivation of potential carcinogens such as N-nitrosamines. Polymorphisms in the gene have been reported to be associated with cancer. The aim of this study was to evaluate genotype distributions and allele frequencies of five CYP2E1 polymorphisms in Iran Materials and Methods: Two hundred healthy individuals of an Iranian population from the southwest were included in this study. PCR-restriction fragment length polymorphism and Tetra-ARMS PCR methods were applied for CYP2E1 genotyping. Results: The allele frequencies for *5B, *6, *7B, *2, and *3 were calculated to be 1.5%, 16%, 28.5%, 0%, and 2.75% respectively. Results of this study showed that no significant differences in genotype and allele frequencies of five single nucleotide polymorphisms with respect to the gender and tribes. The chi-square test showed that the genotype frequencies of CYP2E1*5B were similar to Caucasians, but the distribution of CYP2E1*6 genotypes was similar to Asians. The frequencies of CYP2E1*2 (0%) and CYP2E1*3 (2.75%) alleles were within the range for Caucasians and Orientals. In the case of CYP2E1*7B, the data werelimited. Accordingly, the results were only compared with Europeans and the comparison showed significant differences. Conclusions: In conclusion, ethnic and geographic differences may explain discrepancies in the prevalence of CYP2E1 polymorphisms.
引用
收藏
页码:6505 / 6510
页数:6
相关论文
共 43 条
[1]   CYP2E1PstI/RsaI polymorphism and interaction with tobacco, alcohol and GSTs in gastric cancer susceptibility:: a meta-analysis of the literature [J].
Boccia, Stefania ;
De Lauretis, Angelo ;
Gianfagna, Francesco ;
van Duijn, Cornelia M. ;
Ricciardi, Gualtiero .
CARCINOGENESIS, 2007, 28 (01) :101-106
[2]   CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer [J].
Boccia, Stefania ;
Cadoni, Gabriella ;
Sayed-Tabatabaei, Fakhredin A. ;
Volante, Mariangela ;
Arzani, Dario ;
De lauretis, Angelo ;
Cattel, Caterina ;
Almadori, Giovanni ;
Van Duijn, Cornelia M. ;
Paludetti, Gaetano ;
Ricciardi, Gualtiero .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (01) :93-100
[3]   The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine [J].
Bolt, HM ;
Roos, PH ;
Thier, R .
INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, 2003, 76 (03) :174-185
[4]  
Bouchardy C, 2000, INT J CANCER, V87, P734, DOI 10.1002/1097-0215(20000901)87:5<734::AID-IJC17>3.0.CO
[5]  
2-E
[6]  
Cai L, 2005, WORLD J GASTROENTERO, V11, P1867, DOI 10.3748/wjg.v11.i12.1867
[7]  
Costa GNO, 2012, MOL DIAGN THER, V16, P241, DOI 10.2165/11634480-000000000-00000
[8]  
Danko IM, 2005, EXP ONCOL, V27, P248
[9]   Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity [J].
Ernstgård, L ;
Warholm, M ;
Johanson, G .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (02) :190-200
[10]   Detection and characterization of novel polymorphisms in the CYP2E1 gene [J].
Fairbrother, KS ;
Grove, J ;
de Waziers, I ;
Steimel, DT ;
Day, CP ;
Crespi, CL ;
Daly, AK .
PHARMACOGENETICS, 1998, 8 (06) :543-552